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In July 2016, former President Barack Obama signed the Comprehensive Addiction and Recovery Act 
(CARA) of 2016 into law, establishing a comprehensive federal strategy to combat the opioid crisis 
by expanding prevention and education efforts, and promoting treatment and recovery. In February 
2018, Sen. Rob Portman of Ohio and 10 bipartisan co-sponsors introduced CARA 2.0 to enhance 
the response to the opioid epidemic. This brief provides an overview of the opioid crisis, important 
components of CARA and CARA 2.0, and implications for Georgia. 
The Opioid Epidemic Nationally 
and in Georgia
Opioids are a class of drugs that include the illegal 
drug heroin, synthetic opioids (e.g., fentanyl), and 
prescription pain relievers, such as oxycodone 
(OxyContin®), hydrocodone (Vicodin®), codeine, 
and morphine.1 Recent studies indicate the 
majority of drug overdose deaths (66%) involve an 
opioid,2 with more than 115 Americans dying every 
day from opioid overdoses.3 Opioid overdose 
death rates in the United States increased fivefold 
between 1999 and 2016.3 According to the U.S. 
Department of Health and Human Services (HHS), a driver of this increase in opioid-related deaths 
has been increased prescription opioid use, which in turn led to “widespread misuse” of both 
prescription and nonprescription opioids.4 Historically, over 40% of all opioid overdose deaths have 
involved prescription medications,5 but starting in 2013 with opioid prescribing starting to decline, a 
shift in use toward illicit opioids began to drive opioid overdose deaths.2 In 2017, HHS declared the 
opioid crisis a public health emergency.
Although Georgia’s opioid overdose death rate has trended below the national average, the state’s 
opioid overdose death rate increased nearly 900% from 1999 to 2016 (Figure 1). According to the 
Georgia Department of Public Health (DPH), starting in 2013 illegal opioids were responsible for a 
steep increase in opioid overdose deaths in the state.6 Although opioid prescriptions are starting to 
decline, prescription rates remain high, with the Georgia’s Office of the Attorney General reporting 
that from June 2016 through May 2017 over 541 million opioid doses were prescribed in Georgia, 
translating to 54 doses for each person in the state.7 
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Figure 1. Opioid Overdose Death Rate 
per 100,000 Population (Age-Adjusted)
Source: Kaiser Family Foundation State Health Facts. (2018). Opioid 
Death Rates. Accessed at https://kaiserf.am/2KVnBOi
The opioid crisis also affects pregnant women and newborns. Research shows that use during early 
pregnancy is associated with congenital heart, neural tube, and abdominal wall defects in newborns. 
Opioid use later in pregnancy is associated with neonatal opioid withdrawal syndrome, a cluster of 
symptoms in newborns that include difficulty breathing, extreme drowsiness, poor feeding, irritability, 
sweating, tremors, vomiting and diarrhea, seizures, and even death in severe cases.8, 9 Additionally, 
recent studies suggest that children with prenatal opiate exposure experience weakened cognitive 
abilities, along with an increased risk of behavioral and emotional problems (such as aggression 
and attention deficits).10 DPH reported that in 2016, there were 410 confirmed cases of neonatal 
abstinence syndrome in Georgia, of which nearly 30% tested positive for opioids.11 
CARA 2.0 Key Provisions
CARA established a comprehensive, coordinated federal response to the opioid epidemic, anchored 
by six pillars: prevention, treatment, recovery, law enforcement, criminal justice reform, and overdose 
reversal. CARA 2.0 seeks to build upon efforts in each of the six areas in order to further enhance our 
nation’s response to the opioid crisis.12 Key components of both pieces of legislation are outlined in 
Table 1 below.
Table 1. Key Features of CARA and CARA 2.0, Compared
Pillar CARA13 CARA 2.014 
Prevention • Expanded prevention and educational 
efforts aimed at teens, parents, and 
other caretakers.
• Creates national education campaign 
on prescription opioid misuse.
• Creates three-day limit on initial 
opioid prescriptions for acute pain.
Treatment • Authorized grants to states for 
medication-assisted treatment15  (MAT) 
and evidence-based interventions.
• Expanded ability of physician assistants 
and nurse practitioners to prescribe 
buprenorphine (until Oct. 1, 2021).
• Expanded physician MAT patient load 
caps.
• Permanently expands prescribing 
authority of physician assistants 
and nurse practitioners to prescribe 
buprenorphine.
• Removes caps on physician MAT 
patient load.
• Requires physician participation in 
applicable state prescription drug 
monitoring programs (PDMPs).16 
Recovery • Allowed HHS to award grants for 
recovery services for pregnant women, 
infants, and veterans.
• Establishes a national standard for 
recovery housing.
• Creates the National Youth Recovery 
Initiative to maintain support services 
for youth. 
Overdose Reversal • Expanded availability of naloxone 
(opioid antagonist used to reverse 
overdose) to law enforcement and first 
responders.
• Allocates additional $300 million 
annually to expand naloxone 
availability for first responders.
Law Enforcement • Created a grant program within the 
Department of Justice (DOJ) for states 
to develop a program for treatment 
alternatives to incarceration.
• Enhances safety training for first 
responders about fentanyl and other 
dangerous illicit substances.
Criminal Justice Reform • Expanded resources to identify and 
treat incarcerated individuals with 
substance use disorders by providing 
evidence-based treatment.
• Expands veterans’ treatment courts.
Funding
CARA allocated for $181 million per year, as appropriated by 
Congress. For fiscal year (FY) 2015, Congress authorized $40.93 
million, including $25 million for MAT and $15.93 million for pregnant 
and postpartum women. For FY 2016, Congress appropriated 
$153 million for all aspects of CARA, including DOJ funding, 
first responder training, grants for veterans’ treatment, overdose 
treatment, and MAT. The 21st Century Cures Act, signed in December 
2016, provided $1.1 billion to support the opioid response, including implementation of CARA. In 
March 2018, for FY 2018, Congress appropriated $330 million for CARA, including $75 million for drug 
courts, $30 million for mental health courts and adult and juvenile collaboration program grants, $20 
million for veterans’ treatment courts, $30 million for residential substance abuse treatment for state 
prisoners, $30 million for prescription drug monitoring, and $145 million for a comprehensive opioid 
abuse program.17  
While the FY 2018 spending bill included appropriations for some items in CARA 2.0, CARA 2.0 
expands funding for a broad scope of opioid-related programs, including:18 
• $300 million to expand first responder training and access to naloxone.
• $300 million to expand evidence-based MAT.
• $200 million to build a national infrastructure for recovery support services that help individuals 
move successfully from treatment into long-term recovery.
• $100 million to expand treatment for pregnant and postpartum women, including facilities that 
allow children to reside with their mothers.
• $60 million to help states develop an infant plan of safe care that assists states, hospitals, and 
social services to report, track, and assist newborns exposed to substances and their families.
• $20 million to expand veterans’ treatment courts.
• $10 million for the National Youth Recovery Initiative to develop and support youth recovery 
support services.
• $10 million to fund a national education campaign on the dangers of misuse of prescription 
opioids, heroin, and fentanyl.
Implications for Georgia
Over the past few years, Georgia has made great strides in its response to the opioid crisis. In 2016, 
the National Safety Council rated Georgia as “failing” in response to the opioid crisis, but in April 
2018 the group granted Georgia its highest possible rating of “improving.”19  Some of Georgia’s key 
policies and initiatives aimed at combatting the opioid epidemic include the 911 Medical Amnesty 
Law; a state standing order for naloxone; stricter regulation of pain management prescribing for 
opioids; a PDMP; the Substance Abuse and Mental Health Service Administration-funded Georgia 
Opioid State Targeted Response, which includes a statewide media campaign, naloxone education 
and training, school pilot programs, expansion of MAT, and increased recovery services and peer 
support; and the development of a state strategic plan for opioid response.20, 21, 22, 23 
CARA 2.0 may accelerate the state’s efforts by further expanding MAT, increasing access to naloxone, 
strengthening the PDMP, creating recovery support services, and bolstering the state’s efforts to 
educate health professionals about pain management.18  CARA 2.0 is currently with the Senate 
Judiciary Subcommittee on Crime and Terrorism.14
The Georgia Health Policy Center and Center of Excellence for Children’s Behavioral Health will 
continue to monitor the progress of CARA 2.0, as well as other federal bills and administrative actions 
intended to combat the opioid crisis.
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